The Pharma Data

JANUARY 4, 2021

This collaboration exemplifies our strategy to develop in-house programs for selected retinal targets, while maximizing our proprietary technology platforms with additional collaboration programs for other targets in ophthalmology and further indications,” said Dr. Caroline Man Xu, Co-founder and CEO of ViGeneron.

Gene Therapy 52

Gene Therapy Gene Development In-Vivo 52

Drug Discovery World

DECEMBER 27, 2023

Dr Pierre Eftehkari, Chief Scientific Officer of Inoviem Scientific, joined the podcast series to share his insight into the future of drug development, leaning on his in-depth understanding of the pharmaceutical industry and its needs. The final episode of the year was with Isaac Klein, Chief Scientific Officer of Dewpoint Therapeutics.

Clinical Trials 69

Clinical Trials Clinical Trials Drugs Development 69

The Pharma Data

APRIL 27, 2021

vice president, global therapeutic area head, eye care, AbbVie. The proposed mechanism of action of AGN-190584 is through contraction of the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near and intermediate visual acuity while maintaining some pupillary response to light. NORTH CHICAGO, Ill.

Research 40

Research Drug Delivery Systems Drug Delivery Production 40

XTalks

AUGUST 2, 2023

In this in-depth article, we embark on a captivating journey to uncover the top 30 pharma and biotech companies that have been instrumental in shaping the future of medicine. For example, Ocrevus will be challenged by Novartis’ Kesimpta (ofatumumab) and TG Therapeutics’ Briumvi (ublituximab). But all three drugs have new competitors.

Sales 98

Sales Manufacturing FDA Approval Life Science 98